Bryner R W, Toffle R C, Ullrich I H, Yeater R A
Department of Medicine, School of Medicine, West Virginia University, Morgantown 26506-6116, USA.
Br J Sports Med. 1996 Mar;30(1):36-40. doi: 10.1136/bjsm.30.1.36.
to examine the effect of cycle phase or a low dose oral contraceptive on exercise performance in young women.
As controls, 15 men were tested twice by a maximal treadmill test (Vo2 max) and by an endurance run 14 d apart to determine performance variability from causes other than hormonal fluctuations. Ten women ages 18-30 were then tested for Vo2 max and endurance in the same way in both the follicular and the luteal phase (random order, ovulation assessed by sonography). They were then randomly assigned to placebo (n = 3) or oral contraceptive (1 mg norethindrone and 35 micrograms ethinyl oestradiol) (n = 7) for 21 days. Tests were repeated during the first and third weeks of treatment. Vo2 max and endurance tests were compared in the men and control cycle of the women by using independent t tests on percent change. The data for both cycles in the women were analysed by repeated measures ANOVA.
There was no difference in per cent change in total test time, Vo2 max, or breathing frequency between the men and women in either test. Data obtained during the Vo2 max test revealed no difference between the follicular and luteal phases of the menstrual cycle for total test time [11.8 (SD 2.3) v 12.6 (2.3) min], Vo2 [41.6 (12.1) v 39.7 (11.4) ml.kg-1.min-1], or breathing frequency [26.8 (3.5) v 27.3 (9.9) breaths.min-1] respectively, or during the first and third weeks of treatment [total test time 12.0 (2.5) v 12.8 (2.4) min; Vo2 37.3 (7.4) v 41.0 (12.4) ml.kg-1.min-1; breathing frequency 27.8 (4.2) v 27.7 (3.4) breaths.min-1, respectively]. Data obtained during the endurance test revealed no difference between the follicular and luteal phase of the menstrual cycle for total test time [20.5 (15.7) v 16.2 (8.5) min], Vo2 [37.5 (9.4) v 32.9 (8.1) ml.kg-1.min-1], or breathing frequency [32.0 (6.0) v 33.2 (5.1) breaths.min-1, respectively], or during the first and third weeks of treatment [total test time 32.3 (34.9) v 30.6 (30.1) min; Vo2 33.9 (10.1) v 35.2 (8.6) ml.kg-1.min-1; breathing frequency 34.0 (5.9) v 34.8 (5.3) breaths.min-1, respectively].
Neither cycle phase nor a low dose oral contraceptive containing 1 mg norethindrone adversely affects performance during a maximal treadmill test or endurance run.
研究月经周期阶段或低剂量口服避孕药对年轻女性运动能力的影响。
作为对照,15名男性接受两次最大运动平板试验(最大摄氧量)和耐力跑测试,两次测试间隔14天,以确定除激素波动外其他因素导致的运动能力变异性。随后,10名年龄在18 - 30岁的女性在卵泡期和黄体期以相同方式进行最大摄氧量和耐力测试(随机顺序,通过超声评估排卵情况)。然后将她们随机分为安慰剂组(n = 3)或口服避孕药组(1毫克炔诺酮和35微克炔雌醇)(n = 7),为期21天。在治疗的第一周和第三周重复进行测试。通过独立t检验比较男性和女性对照周期中最大摄氧量和耐力测试的百分比变化。对女性两个周期的数据进行重复测量方差分析。
在两项测试中,男性和女性的总测试时间、最大摄氧量或呼吸频率的百分比变化均无差异。最大摄氧量测试数据显示,月经周期的卵泡期和黄体期在总测试时间[11.8(标准差2.3)对12.6(2.3)分钟]、最大摄氧量[41.6(12.1)对39.7(11.4)毫升·千克⁻¹·分钟⁻¹]或呼吸频率[26.8(3.5)对27.3(9.9)次·分钟⁻¹]方面均无差异,在治疗的第一周和第三周也是如此[总测试时间12.0(2.5)对12.8(2.4)分钟;最大摄氧量37.3(7.4)对41.0(12.4)毫升·千克⁻¹·分钟⁻¹;呼吸频率27.8(4.2)对27.7(3.4)次·分钟⁻¹]。耐力测试数据显示,月经周期的卵泡期和黄体期在总测试时间[20.5(15.7)对16.2(8.5)分钟]、最大摄氧量[37.5(9.4)对32.9(8.1)毫升·千克⁻¹·分钟⁻¹]或呼吸频率[32.0(6.0)对33.2(5.1)次·分钟⁻¹]方面均无差异,在治疗的第一周和第三周也是如此[总测试时间32.3(34.9)对30.6(30.1)分钟;最大摄氧量33.9(10.1)对35.2(8.6)毫升·千克⁻¹·分钟⁻¹;呼吸频率34.0(5.9)对34.8(5.3)次·分钟⁻¹]。
月经周期阶段或含1毫克炔诺酮的低剂量口服避孕药均不会对最大运动平板试验或耐力跑期间的运动能力产生不利影响。